Relevance of novel inflammatory markers in stroke-induced immunosuppression by Folyovich, András et al.
Folyovich et al. BMC Neurology 2014, 14:41
http://www.biomedcentral.com/1471-2377/14/41RESEARCH ARTICLE Open AccessRelevance of novel inflammatory markers in
stroke-induced immunosuppression
András Folyovich1, Enikő Biró2, Csaba Orbán2, Anna Bajnok2, Viktória Varga1, Anna K Béres-Molnár1,
Barna Vásárhelyi3 and Gergely Toldi2*Abstract
Background: Acute ischemic stroke (AIS) has a biphasic effect on the peripheral immune system. The initial
inflammatory response is followed by systemic immunosuppression, referred to as stroke-induced immunosuppression
(SIIS), leading to severe complications in stroke patients. We aimed to identify an inflammatory marker that best represents
this biphasic immunological response after AIS.
Methods: We investigated the alteration of CRP, WBC, neutrophil count, suPAR levels, CD4+ CD25high Tregs, CD64+ and
CD177+ neutrophils and monocytes in 12 acute ischemic stroke patients free of infection within 6 hours and one week
after the insult. As controls, 14 age-matched healthy individuals were included.
Results: CRP, WBC and neutrophil count values were comparable in stroke patients within 6 hours and controls, however,
they were elevated in stroke one week after the insult. suPAR levels were higher in both stroke groups compared to
controls. The prevalence of CD64+ neutrophils was higher in stroke patients within 6 hours than in controls and it
decreased in stroke one week after the insult below the level in controls (5.95 [5.41-8.75] % vs. 32.38 [9.21-43.93] % vs. 4.06
[1.73-6.77] %, p < 0.05).
Conclusions: Our pilot study identified that the prevalence of CD64+ neutrophils may reflect a biphasic alteration of the
immune response following AIS. Since its level decreases below baseline after one week of the CNS insult in stroke
patients without infection, it might serve as a reliable candidate to identify the developing inflammatory response due to
infection after stroke in the future.
Keywords: CD4+ lymphocyte, CD64+ neutrophil, CRP, Stroke, suPAR, TregBackground
Animal data clearly support a biphasic effect of stroke
on the peripheral immune system. The initial phase is
characterized by a local and then a generalized inflam-
matory response, resulting in a massive production of
inflammatory factors and extravasation of lymphocytes
to the brain. This early activation phase is followed by
systemic immunosuppression, referred to as stroke-
induced immunosuppression (SIIS) that is manifested
within days of focal stroke by a reduction in T cell acti-
vation and a profound loss of T and B cells [1]. While
both immune activation and suppression can be ob-
served in stroke patients and in experimental stroke, the* Correspondence: toldigergely@yahoo.com
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reproduction in any medium, provided the ortemporal relationship of these immune alterations has
not been clearly delineated.
The role of aberrant systemic immune function in post-
stroke infection has only been recently demonstrated in
clinical studies [2]. Infection during the first days after AIS
occurs in 25-65% of patients [3]. Pneumonia and urinary
tract infection are the most common infectious complica-
tions [4], causing a significant increase in the duration of
hospitalization. Therefore, from a clinical point of view, it is
of great importance to distinct the inflammatory response
induced by CNS damage and that later caused by evolving
infection. Markers of infection currently used in clinical
practice are unreliable for the distinction between the two
different origins of an inflammatory response in AIS. Stroke
is associated with an increase of classic markers of the in-
flammatory response, such as C-reactive protein (CRP)
[5,6], erythrocyte sedimentation rate (ESR) [6], totalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Demographic data and risk factors of controls
and acute ischemic stroke patients
Control (n = 14) Stroke (n = 12)
Age, years 62,5 [52–71] 67,5 [60–76]
Male/female 7/7 4/8
Hypertension 7 (50%) 9 (75%)
Smoking 3 (21%) 4 (33%)
Alcohol 4 (29%) 4 (33%)
Obesity 4 (29%) 4 (33%)
Earlier CVD 4 (29%) 5 (42%)
Cholesterinemia 2 (14%) 2 (17%)
Diabetes 2 (14%) 4 (33%)
Atrial fibrillation 2 (14%) 4 (33%)
Modified rankin score - 4 (1–5)
NIHSS score at admission - 5.5 [4-15]
TOAST classification - 1: 5 (42%); 2: 4 (33%);
3: 3 (25%)
Largest diameter of the
infarct, mm
- 27 [16–37,5]
Data are expressed as median [IQR] or number (%).
CVD – cardiovascular disease.
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http://www.biomedcentral.com/1471-2377/14/41peripheral white blood cell (WBC) count [7], peripheral
neutrophil count [6] and body temperature [8]. It has also
been demonstrated though that the elevation of the above
markers is independent of the presence of infection [9].
Nevertheless, novel markers of inflammation have been
emerging and becoming available for clinical diagnostic
testing. Among these markers the two most promising ones
are soluble urokinase plasminogen activator receptor
(suPAR) and the CD64 antigen expression.
suPAR is a biomarker increasingly used for the monitor-
ing of systemic inflammation. suPAR is derived from the
cleavage and release of the membrane-bound protein,
urokinase-type plasminogen activator receptor (uPAR),
expressed by various cell types, such as trophoblasts, endo-
thelial cells, smooth muscle cells, certain tumor cells, and
most importantly, immunologically active cells including
monocytes, activated T lymphocytes and macrophages [10].
CD177, also known as NB1 is a 55-kDa receptor that be-
longs to the uPAR family. It is expressed on a subpopula-
tion of neutrophils and monocytes, and is regarded as a
marker of extravasation [11]. Cell migration is tightly linked
to adhesion and chemotaxis. The uPAR system is directly
involved in these mechanisms [12]. suPAR is detectable in
low, but constant concentrations in plasma of healthy indi-
viduals. However, activation of the immune system and the
development of an inflammatory response lead to elevated
plasma suPAR concentrations [13].
In resting neutrophils, Fc gamma receptor I (FcgRI,
CD64) is expressed at very low levels; upon neutrophil acti-
vation it is strongly upregulated by the proinflammatory cy-
tokines IFN-gamma and granulocyte colony stimulating
factor (G-CSF) which are produced during infections or ex-
posure to endotoxin [14]. Monocytes also express CD64
and upregulate this receptor during activation. Neutrophil
and monocyte CD64 expression, demonstrated using flow
cytometry, can be used as a diagnostic marker of infection
and sepsis. Neutrophil CD64 is superior to CRP and
hematological determinations for detecting systemic infec-
tion or sepsis, since it combines high sensitivity (above
90%) with high specificity (90-100%) [15].
In this study, we aimed to describe the alteration of
selected clinical inflammatory markers (CRP, WBC, neu-
trophil count, suPAR, CD64 neutrophil and monocyte
antigen expression) in AIS in order to identify an inflam-
matory marker that best represents the biphasic im-
munological response following the CNS insult. We also
aimed to describe the prevalence of immunosuppressive
CD4+ CD25high Treg cells, activated (CD11b+) mono-
cytes, as well as the prevalence of CD177+ neutrophils
and monocytes.
Methods
Peripheral blood samples were taken from 12 identical
AIS patients within 6 hours (Stroke 1) and one weekafter the insult (Stroke 2). AIS was defined according to
the WHO definition [16]. Patients with subarachnoid
haemorrhage, epidural or subdural hemorrhage, transi-
ent ischaemic attack (TIA) or neurological deficit due to
trauma or neoplasm were excluded. Based on positive
microbial cultures, patients with infection after stroke
were also excluded. The severity of stroke was assessed
using the modified NIHSS and Rankin scores upon ad-
mission [17]. As controls, 14 age-matched healthy indi-
viduals with similar cardiometabolic risk factors were
included from whom peripheral blood samples were
taken on a single occasion. Healthy controls had a nega-
tive history of stroke or other neurological disorders.
Demographic data and risk factor profiles of patients
and controls are shown in Table 1. Written informed
consent was obtained from all subjects, and our study
was reviewed and approved by an independent ethical
committee of the institution (Szent János Hospital,
Budapest). Laboratory studies and interpretations were
performed on coded samples lacking personal and diag-
nostic identifiers. The study was adhered to the tenets of
the most recent revision of the Declaration of Helsinki.
Plasma was isolated from heparin anticoagulated blood
samples and stored at −80°C until measurement. Plasma
suPAR concentrations were measured with the suPAR-
nostic Flex ELISA assay (ViroGates A/S, Birkerød,
Denmark). CRP levels were measured using a Roche
Hitachi 912 instrument with Roche Tina-quant CRP
immuno-turbidimetric assay (Roche Diagnostics GmbH,
Mannheim, Germany). Blood count values were
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analyzer (Beckman Coulter, Brea, CA, USA).
300 ul heparin anticoagulated whole blood was incu-
bated with the following conjugated anti-human anti-
bodies: CD4 APC (Miltenyi Biotec, Bergisch Gladbach,
Germany), CD11b PE-Cy7 (BD Biosciences, San Jose,
CA, USA), CD25 APC-Cy7 (BioLegend, San Diego, CA,
USA), CD177 FITC (BioLegend), CD64 PE (BD Biosci-
ences). After 30 minutes of incubation at 4°C, we added
FACS Lysing Solution to each sample (BD Biosciences).
Cells were incubated for 20 min in dark at room
temperature and then were washed. After washing,
500,000 cells were recorded from each sample. Flow cy-
tometry measurements were conducted on a BD FAC-
SAria flow cytometer (BD Biosciences). Data acquired
from the measurements were evaluated with FlowJo soft-
ware (version 7.6.3, Tree Star, Ashland, OR, USA). The
gating strategy is shown in Figure 1.
Data are expressed as median [interquartile range].
CRP values below the level of detection (1 mg/L) were
regarded as 1 mg/L. Comparisons between healthy indi-
viduals and AIS patients were made with Mann–
Whitney tests. In case of comparisons between samplesFigure 1 Gating strategy for flow cytometry measurements. FSC – forwtaken at different time points of AIS patients, the Wilcoxon
signed rank test was performed. Correlation analyses
were performed using Spearman’s tests. p values less
than 0.05 were considered significant. Statistics were
calculated using the SPSS software (version 20.0, SPSS,
Inc. Chicago, IL, USA).Results
Our results are summarized in Figure 2 and Table 2.
CRP, WBC and neutrophil count values were compar-
able in Stroke 1 and controls, however, they were ele-
vated in Stroke 2. No difference in monocyte and
lymphocyte counts or the prevalence of CD11b +mono-
cytes was observed between the study groups. The
prevalence of CD4+ lymphocytes decreased in Stroke 1
compared to controls, and increased again in Stroke 2
compared to Stroke 1. The prevalence of CD4+
CD25high Treg cells did not differ significantly between
the study groups, although a tendency of increased Treg
prevalence was observed in Stroke 2.
suPAR levels were higher in stroke patients at both
time points compared to controls.ard scatter, SSC – side scatter, Treg – regulatory T cells.
Figure 2 Selected inflammatory parameters in controls and acute ischemic stroke patients measured within 6 hours (Stroke 1) and one
week after (Stroke 2) the insult. The prevalence of CD64+ neutrophils may reflect a biphasic alteration of the immune response in acute
ischemic stroke patients free of infection (inflammation followed by immunosuppression). Horizontal line – median, box – IQR, whisker – range.
*p < 0.05 vs. Control, #p < 0.05 vs. Stroke 1. CRP – C-reactive protein, suPAR – soluble urokinase plasminogen activator receptor, WBC – white
blood cell count.
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Stroke 1 than in controls. However, their prevalence de-
creased in Stroke 2 below the level in controls. The
prevalence of CD177+ neutrophils was higher in both
stroke groups compared to controls. Mean fluorescence
intensity (MFI) of CD64 and CD177 in neutrophils
was comparable in all study groups. The prevalence of
CD64+ CD177+ neutrophils was lower in Stroke 2 com-
pared to the two other study groups, and showed a
tendency of elevation in Stroke 1 compared to controls.
The prevalence of CD64+ monocytes was comparable
in all study groups, while that of CD177+ monocytes
was higher in both stroke groups compared to controls.
MFI of CD64 in monocytes was lower in Stroke 2 com-
pared to Stroke 1, while that of CD177 was comparable
in all study groups. The prevalence of CD64+ CD177+
monocytes was also comparable in all study groups.
No correlation was detected between plasma suPAR
levels and the expression of CD177 on neutrophils or
monocytes in any of the study groups. Furthermore, we
found no correlation between markers of stroke severity
(modified Rankin and NIHSS scores) and the prevalence
of CD64+ neutrophils in AIS patients.Discussion
Stroke is a major cause of disability and mortality in de-
veloped countries [18]. However, this is not only due to
the neurological deficit caused by the brain lesion. It is
now clear that AIS results in multi-organ systemic dis-
ease that occurs within the context of the complex inter-
play between the brain and immune system. While acute
stroke patients may survive the initial CNS insult, subse-
quent complications might develop over time. SIIS,
resulting in an increased risk of infections, is the most
common of these complications, causing a significant in-
crease in the duration of hospitalization [19]. SIIS also
hinders the regeneration process of the CNS, and there-
fore worsens the functional outcome of patients. There-
fore, in our pilot study we aimed to describe the
alteration of selected clinical inflammatory markers in
AIS.
As outlined below, most investigations report that al-
terations caused by SIIS are already present one week
following the insult. Therefore, we chose to analyze pa-
tient samples one week after admission. Compared to
our findings, Emsley et al. reported that CRP concentra-
tion was significantly higher in AIS patients earlier, even
Table 2 Inflammatory parameters in controls and acute ischemic stroke patients measured within 6 hours (stroke 1)
and one week after (stroke 2) the insult
Control (n = 14) Stroke 1 (n = 12) Stroke 2 (n = 12)
suPAR, ng/mL 3.62 [3.30-4.91] 5.04 [3.93-6.58]a 4.64 [4.15-6.35]a
CRP, mg/L 2.37 [1.40-3.36] 2.83 [1.98-4.15] 11.48 [9.73-20.52]ab
WBC, 109/L 6.38 [5.35-8.58] 7.42 [5.50-8.81] 10.87 [7.85-13.90]ab
Neutrophil, 109/L 4.50 [3.54-5.49] 5.97 [4.11-7.68] 8.10 [5.82-11.75]ab
CD64+/neutrophil, % 5.95 [5.41-8.75] 32.38 [9.21-43.93]a 4.06 [1.73-6.77]ab
CD64 MFI/neutrophil, au 262 [145–505] 331 [205–528] 258 [93–838]
CD177+/neutrophil, % 53.24 [44.10-65.58] 76.95 [47.18-89.68]a 73.46 [44.55-84.28]a
CD177 MFI/neutrophil, au 3780 [2112–4859] 5887 [4429–9455] 6208 [3143–6899]
CD64+ CD177+/neutrophil, % 2.78 [1.71-3.79] 21.30 [0.98-31.58] 0.99 [0.80-1.79]ab
Monocyte, 109/L 0.40 [0.38-0.53] 0.45 [0.33-0.68] 0.50 [0.40-0.68]
CD11b+/monocyte, % 83.50 [68.30-89.03] 84.55 [73.60-91.22] 89.90 [76.08-94.03]
CD64+/monocyte, % 31.32 [14.65-56.20] 22.51 [10.00-45.65] 15.29 [5.80-36.34]
CD64 MFI/monocyte, au 280 [69–610] 955 [223–1658] 142 [42–365]b
CD177+/monocyte, % 26.09 [11.81-40.53] 36.15 [23.83-61.22]a 43.47 [30.52-67.97]a
CD177 MFI/monocyte, au 2293 [1378–3625] 4705 [1774–6483] 2492 [1479–3503]
CD64+ CD177+/monocyte, % 1.43 [0.65-2.36] 2.50 [0.69-4.21] 1.15 [0.77-1.94]
Lymphocyte, 109/L 1.49 [0.96-2.25] 1.24 [0.70-1.50] 1.34 [0.53-1.84]
CD4+/lymphocyte, % 35.41 [27.51-44.17] 9.08 [3.85-23.96]a 22.13 [18.41-41.86]b
CD4+ CD25high/CD4+, % 9.38 [7.52-13.95] 10.46 [9.40-13.13] 14.59 [8.97-18.25]
Data are expressed as median [IQR]. ap < 0.05 vs. Control, bp < 0.05 vs. Stroke 1. au – arbitrary unit, CRP – C-reactive protein, MFI – mean fluorescence intensity,
suPAR – soluble urokinase plasminogen activator receptor, WBC – white blood cell count.
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comparison with control subjects, reaching a peak at 5–
7 days after stroke onset. Similarly, total WBC and neu-
trophil counts were elevated from admission until
3 months. By 12 months, no differences from control
subjects were detectable in CRP, WBC or neutrophil
values. Similar differences in these values were seen
when patients with evidence of infection were excluded,
although they were somewhat less marked [9]. Accord-
ing to the authors, the relatively early increase in these
markers after stroke may have two possible explanations.
First, that stroke induces a very early inflammatory re-
sponse that is sustained for a long time. Second, the data
may indicate a pre-existing inflammatory condition in
stroke patients which could contribute to the develop-
ment of stroke. The concept of a pre-existing inflamma-
tory condition is supported by evidence that low-grade
inflammation, identified by an elevated CRP concentra-
tion, may be a risk factor for stroke [20]. However, this
concept is not supported by our data, indicating no dif-
ference between CRP values of the Stroke 1 group and
controls. In the report of Emsley and colleagues, median
admission CRP for all patients was raised relative to con-
trols, although this increase was not significant for pa-
tients sampled less than 4 hours from onset [9].
Therefore, the difference between their and our findingsat admission in these values might be due to different
chronologic definition of the first blood sampling.
It has recently gained attention that cerebral ischemia
does not only lead to local inflammation of the brain tissue
and a generalized inflammatory response, but also to a dra-
matic loss of peripheral blood Tcells with subsequent infec-
tions. Therefore, as well as evidence of immune activation,
there is also evidence of post-stroke immune suppression.
The results of Vogelgesang et al. indicated that stroke in-
duced a dramatic and immediate loss of T lymphocytes,
most pronounced within 12 hours after stroke onset. Only
patients with subsequent infection exhibited a delay in the
recovery of CD4+ T lymphocyte counts. They suggest that
a loss of CD4+ T cells contributes to SIIS. The authors
argue that CD4+ T cell count on the day after stroke may
emerge as a predictive marker for post-stroke infection
[21]. Their observation is reinforced by our findings, indeed
showing a loss of CD4+ T cells even within 6 hours after
stroke onset, and a recovery of CD4+ T cell prevalence one
week after the insult in the lack of infection. While both
immune activation and immune suppression can be ob-
served in stroke patients and in experimental stroke, the
temporal relationship of these immune alterations has not
been clearly delineated. Also in the population studied here
the temporal alterations in immune functions may be more
complex.
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increased immunoregulatory activity, possibly by activa-
tion of Treg cells. Indeed, they found that the percent-
ages of FoxP3+ regulatory T cells were significantly
increased from day 7 following the CNS insult in pa-
tients with AIS compared to healthy subjects [22]. Al-
though the prevalence of CD4+ CD25high Treg cells did
not differ significantly between the study groups in our
investigation, a tendency of increased Treg prevalence
was observed one week after the insult compared to the
initial values in stroke patients and controls. The differ-
ence seen between our and their results might be due to
the fact that different markers were used for the detec-
tion of Tregs (in our study, this subset was described as
CD4+ CD25high cells, and FoxP3 was not applied) and
that the severity of stroke was different in the two inves-
tigations. The patients examined by Yan et al. had
relatively mild disease (average NIHSS was 3.6, corre-
sponding to minor stroke), while our patients developed
severe disability already within 6 hours (average modi-
fied Rankin score was 4).
suPAR has earlier been demonstrated to be elevated in
sera, but not in CSF of stroke patients [23]. Our results
indicate that suPAR levels were elevated already within
6 hours of the insult, earlier than CRP, WBC or neutro-
phil counts. Hence, suPAR is an earlier indicator of the
inflammatory response developing due to the CNS in-
sult. The increase in the prevalence of uPAR expressing
(CD177+) neutrophils and monocytes indicates the
higher susceptibility of these cells for extravasation and
infiltration of the lesion both within 6 hours and one
week after the insult. MFI values of CD177 were not al-
tered, showing that the amount of receptors per cell is
constant. Interestingly, we could not detect a correlation
between plasma suPAR levels and the expression of
CD177 on neutrophils or monocytes in any of the study
groups. suPAR is believed to have inhibiting properties
on uPAR-dependent adhesion, as it competes with cell
surface bound uPAR for binding integrin and vitronectin
molecules at the focal contacts [24]. This competition
might have a regulatory effect on uPAR expression and
on the cleavage of the membrane-bound form of the
protein.
Neutrophil granulocytes express FcgRI (CD64) antigen
only when activated. Its expression rises in bacterial infec-
tion, thus it is increasingly used as a diagnostic marker for
sepsis [15]. Based on our current findings, influences other
than infection, such as stroke-related inflammation may
also rapidly increase CD64 expression. Our results indicate
that the prevalence of CD64+ neutrophils increase within
6 hours and falls back by one week after the CNS insult
even below the baseline measured in the healthy control
group, most closely representing the biphasic immuno-
logical response characteristic for AIS (inflammationfollowed by immunosuppression). Therefore, upon infec-
tion, the prevalence of CD64+ neutrophils may rise again,
while since the level of the other investigated inflammatory
parameters remain elevated even without infection, their
alteration would not be specific for inflammation of
infectious origin. The decrease of CD64 expression on
neutrophils might be due to the evolving immuno-
suppressive mechanisms and the consolidation of the
inflammatory response. In contrast to neutrophils, such
alterations were not detected in the prevalence of CD64+
monocytes, although MFI of the CD64 antibody did de-
crease one week after the insult compared to the onset of
stroke.
Limitations of our study include small sample size, dif-
ferences in sex ratio of patients and controls and the
lack of AIS patients with confirmed infection. Based on
our current results, more focused studies in the future
may also provide an opportunity to perform detailed
analysis on subgroups of stroke patients. Further sub-
group analysis based on stroke subtype on larger sam-
ples might also provide additional information on
differences of the degree of inflammatory activation. For
instance, Licata et al. observed significant differences in
inflammatory parameters between lacunar and non-
lacunar ischemic stroke patients [25-27].Conclusions
In conclusion, our pilot study identified that the prevalence
of CD64+ neutrophils may reflect a biphasic alteration of
the immune response following AIS. Since its level de-
creases below baseline after one week of the CNS insult in
AIS patients without infection, it might serve as a reliable
candidate to identify the developing inflammatory response
due to infection after stroke. However, further clinical stud-
ies are needed to test its usefulness in the distinction of the
infection-induced inflammatory response in AIS patients
developing infection.
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